Preparations methods of tizanidine (API) and related compounds: A review

Tizanidine is an imidazoline derivative with the agonistic activity of central alpha 2 receptors at both the spinal and supra-spinal levels. It was prepared for the first time in 1978 and approved for use in 1996. The present review focuses on all methods used for the synthesis of tizanidine, related compounds and intermediates. This review article covers all the methods that have been used in the preparation of tizanidine since its discovery until now. Methods used for the preparation of tizanidine-related compounds are also covered. This review gives those interested in drug synthesis and designs the ability to form a complete picture of the preparation of this drug, as well as providing the opportunity for the synthesis of other drugs developed from this drug to increase activity and/or reduce side effects.

[1]  Jennifer E. Moore,et al.  Agency for Healthcare Research and Quality , 2020, Definitions.

[2]  A. Ellern,et al.  Open-Resonance-Assisted Hydrogen Bonds and Competing Quasiaromaticity. , 2018, The Journal of organic chemistry.

[3]  Daize Mo,et al.  Chlorination of Low-Band-Gap Polymers: Toward High-Performance Polymer Solar Cells , 2017 .

[4]  S. Mense.  Muscle pain: mechanisms and clinical significance. , 2008, Deutsches Arzteblatt international.

[5]  J. D. Runyan,et al.  A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients , 2008, International journal of clinical practice.

[6]  L. Kamen,et al.  A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. , 2008, Current medical research and opinion.

[7]  G. Malanga,et al.  Update on tizanidine for muscle spasticity and emerging indications. , 2008, Expert opinion on pharmacotherapy.

[8]  E. Beard,et al.  The American Society of Health System Pharmacists. , 2001, JONA's Healthcare Law, Ethics, and Regulation.

[9]  A. Wagstaff,et al.  Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. , 1997, Drugs.

[10]  C J Mathias,et al.  Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. , 1989, Journal of rehabilitation research and development.

[11]  M. Weinberger,et al.  NUCLEAR MAGNETIC RESONANCE AND INFRARED STUDIES OF ACYLATED IMIDAZOLIDINONES AND IMIDAZOLIDINETHIONES , 1965 .

[12]  Walter T. Smith,et al.  Preparation of 2,1,3-Benzothiadiazoles Using Dimethylformamide-Sulfur Dioxide Reagent1 , 1962 .

[13]  J. E. Baer,et al.  Acetylation and S-Alkylation of Ethylene Thiourea1 , 1954 .